Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 3/2011

01-06-2011

Atherosclerosis: An Epigenetic Balancing Act that Goes Wrong

Authors: Gertrud Lund, Silvio Zaina

Published in: Current Atherosclerosis Reports | Issue 3/2011

Login to get access

Abstract

Increasing evidence points to dietary lipids and their derivates as dynamic modulators of pro- or anti-inflammatory gene expression pathways via their ability to interact with nuclear receptors that are central to the regulation of numerous biological functions, including lipid metabolism, inflammatory mediator production, and vascular homeostasis. The biological effects of these receptors are the result of a finely tuned equilibrium between gene activation and repression, resulting from their ability to switch between chromatin-remodelling co-repressor and co-activator partners. The aim of this review is to discuss the concept that selected dietary components induce an atherosclerotic cellular phenotype, at least in part, by imposing epigenetic marks that shift the physiologic program of differential gene activation and repression. Aberrant epigenetic marks are seeded in promoter sequences as well as in intragenic sequences where they might regulate transcript splicing.
Literature
1.
The global burden of disease: 2004 update. WHO; 2008.
2.
Stevens G, Dias RH, Thomas KJA, et al. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. PLoS Med. 2008;5:e125.PubMedCrossRef
3.
4.
Murr R. Interplay between different epigenetic modifications and mechanisms. Adv Genet. 2010;70:101–41.PubMedCrossRef
5.
Berstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–81.CrossRef
6.
Nicolaou G, Erridge C. Toll-like receptor-dependent lipid body formation in macrophage foam cell formation. Curr Opin Lipidol. 2010;21:427–33.PubMedCrossRef
7.
Newman PE. Can reduced folic acid and vitamin B12 cause deficient DNA methylation producing mutations which initiate atherosclerosis? Med Hypotheses. 1999;53:421–4.PubMedCrossRef
8.
Mangoni AA. Folic acid, inflammation, and atherosclerosis: false hopes or the need for better trials? Clin Chim Acta. 2006;367:11–9.PubMedCrossRef
9.
Laukkanen MO, Mannermaa S, Hiltunen MO, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19:2171–8.PubMed
10.
Hiltunen MO, Turunen MP, Häkkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7:5–11.PubMedCrossRef
11.
Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004;279:29147–54.PubMedCrossRef
12.
Castillo-Díaz SA, Garay-Sevilla ME, Hernández-González MA, Solís-Martínez MO, Zaina S. Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med. 2010;26:691–700.PubMed
13.
Bird A, Taggart M, Frommer M, Miller OJ, Macleod D. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell. 1985;40:91–9.PubMedCrossRef
14.
Kim M, Arakawa K, Wang R, et al. DNA methylation as a biomarker for cardiovascular disease risk. PLoS ONE. 2010;5:e9692.PubMedCrossRef
15.
Post WS, Goldschmidt-Clermont PJ, Willhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999;43:985–91.PubMedCrossRef
16.
Zhu S, Goldschmidt-Clermont PJ, Dong C. Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation. 2005;112:1353–61.PubMedCrossRef
17.
Devlin AM, Singh R, Wade RE, et al. Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. J Biol Chem. 2007;282:37082–90.PubMedCrossRef
18.
Zawadzki C, Chatelain N, Delestre M, et al. Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis. 2009;204:e4–14.PubMedCrossRef
19.
• Barrès R, Osler ME, Yan J, et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab. 2009;10:189–98. This is the first direct demonstration that a pro-inflammatory fatty acid is capable of inducing global DNA methylation changes. PubMedCrossRef
20.
Hansen AE. Role of dietary fat in human nutrition. I. Role of unsaturated dietary fat in infant nutrition. Am J Public Health Nations Health. 1957;47:1367–70.PubMedCrossRef
21.
Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 2003;23:5293–300.PubMedCrossRef
22.
Massiera F, Barbry P, Guesnet P, et al. A Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J Lipid Res. 2010;51:2352–61.PubMedCrossRef
23.
•• Lycko F, Foret S, Kucharski R, et al. The honey bee epigenomes: differential methylation of brain DNA in queens and workers. PLoS Biol. 2010;8:e1000506. This is a genome-wide analysis of diet-specific DNA methylation patterns in honeybees. Intragenic sequences represent a significant portion of differentially methylated sequences, which is likely to underlie differential transcript splicing profiles. CrossRef
24.
•• Kucharski R, Maleszka J, Foret S, Maleszka R. Nutritional control of reproductive status in honeybees via DNA methylation. Science. 2008;319:1827–30. This article is a demonstration that a differential dietary regime is associated with specific DNA methylation patterns. PubMedCrossRef
25.
Yang TP, Agellon LB, Walsh A, Breslow JL, Tall AR. Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice. Exon exclusion modulates gene expression in response to dietary or developmental change. J Biol Chem. 1996;271:12603–9.PubMedCrossRef
26.
Dessí M, Motti C, Cortese C, et al. Alternative splicing of human plasma cholesteryl ester transfer protein mRNA in Caco-2 cells and its modulation by oleic acid. Mol Cell Biochem. 1997;177:107–12.PubMedCrossRef
27.
Burdge GC, Lillycrop KA. Nutrition, epigenetics, and developmental plasticity: implications for understanding human disease. Annu Rev Nutr. 2010;30:315–39.PubMedCrossRef
28.
Mukherjee S. Adult onset atherosclerosis may have its origin in the foetal state in utero. Curr Opin Lipidol. 2009;20:155–6.PubMedCrossRef
29.
Huang W, Glass CK. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol. 2010;30:1542–9.PubMedCrossRef
30.
Welsh JS, Ricote M, Akiyama TE, et al. PPAR gamma and PPAR delta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. PNAS. 2003;100:6712–7.CrossRef
31.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPAR gamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–20.PubMedCrossRef
32.
Babaev VR, Yancey PG, Ryzhov SV, et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1647–53.PubMedCrossRef
33.
Regieli JJ, Jukema JW, Doevendans PA, et al. PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. Diab Care. 2009;32:839–44.CrossRef
34.
Kanda T, Brown JD, Orasanu G, et al. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest. 2009;119:110–24.PubMed
35.
Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem. 2010 Oct 18, [Epub ahead of print].
36.
Spencer NF, Poynter ME, Im SY, Daynes RA. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol. 1997;9:1581–8.PubMedCrossRef
37.
• Stein S, Lohmann C, Handschin C, et al. ApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis. PLoS One. 2010;5:13539. This is a demonstration of the dual activity of PPARs. Co-activator PPAR partners can exert pro-inflammatory effects in addition to the well-established repressive activity of PPARs on NF-κB and other inflammation markers. CrossRef
38.
Zhang Y, Luo Z, Ma L, et al. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med. 2010;25:729–34.PubMedCrossRef
39.
Rahman M, Halade GV, Bhattacharya A, Fernandes G. The fat-1 transgene in mice increases antioxidant potential, reduces pro-inflammatory cytokine levels, and enhances PPAR-gamma and SIRT-1 expression on a calorie restricted diet. Oxid Med Cell Longev. 2009;2:307–16.PubMedCrossRef
40.
Maloney E, Sweet IR, Hockenbery DM, et al. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009;29:1370–5.PubMedCrossRef
41.
• Coll T, Palomer X, Blanco-Vaca F, et al. Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology. 2010;151:537–48. This is a demonstration that distinct fatty acids differentially regulate inflammation by activating specific and cross-talking pathways involving PPARs and TLR, respectively. PubMedCrossRef
42.
Narala VR, Adapala RK, Suresh MV, et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem. 2010;285:22067–74.PubMedCrossRef
43.
• Hamza MS, Pott S, Vega VB, et al. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. Genes Dev. 2008;22:2953–67. This is an exhaustive mapping of PPAR binding site across the genome. CrossRef
44.
• Nielsen, R, Pedersen TA, Hagenbeek D, et al. Genome-wide profiling of PPARgamma: RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. PLoS. 2010;5:e13539. This is an exhaustive mapping of PPAR binding site across the genome, with additional focus on promoter targets.
45.
Choi JK. Contrasting chromatin organization of CpG islands and exons in the human genome. Genome Biol. 2010;11:R70.PubMedCrossRef
46.
Choy MK, Movassagh M, Goh HG, et al. Genome-wide conserved consensus transcription factor binding motifs are hyper-methylated. BMC Genomics. 2010;11:519.PubMedCrossRef
47.
Carpinteyro-Espín P, Jacinto-Ruíz S, Caballero-Vazquez P, Alvarado-Caudillo Y, Lund G, Rodríguez-Rios D, et al. Organomegaly and tumours in transgenic mice with targeted expression of HpaII methyltransferase in smooth muscle cells. Epigenetics. 2011;6 (in press).
48.
Tartof KD, Bremer M. Mechanisms for the construction and developmental control of heterochromatin formation and imprinted chromosome domains. Dev Suppl. 1990;35–45.
49.
Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27:351–7.PubMedCrossRef
50.
Kerkel K, Spadola A, Yuan E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet. 2008;40:904–8.PubMedCrossRef
Metadata
Title
Atherosclerosis: An Epigenetic Balancing Act that Goes Wrong
Authors
Gertrud Lund
Silvio Zaina
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 3/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0174-3

Other articles of this Issue 3/2011

Current Atherosclerosis Reports 3/2011 Go to the issue

ReviewPaper

Genetic Mechanisms Mediating Atherosclerosis Susceptibility at the Chromosome 9p21 Locus

Clinical Trial Report

Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk

ReviewPaper

Genetics of Redox Systems and Their Relationship with Cardiovascular Disease

ReviewPaper

Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies

ReviewPaper

Update on HDL Receptors and Cellular Cholesterol Transport

ReviewPaper

Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits